Treatment with Metformin Can Improve Insulin Resistance and Lipid Profile in Non-Diabetic Iraqi Women with Polycystic Ovary Syndrome.

تتناول المقالة فعالية الميتفورمين في تحسين مقاومة الأنسولين وملفات الدهون لدى النساء العراقيات غير المصابات بالسكري واللواتي يعانين من متلازمة المبيض المتعدد الكيسات (PCOS). أظهرت دراسة شملت 200 امرأة أنه بعد ثلاثة أشهر من علاج الميتفورمين، كانت هناك انخفاضات ملحوظة في مستوى السكر في الدم الصائم، ومستويات الأنسولين، والهيموغلوبين الغليكوزي (HbA1c)، ومستويات الدهون، على الرغم من أن مؤشر كتلة الجسم (BMI) لم يتغير بشكل ملحوظ. تشير النتائج إلى أن الميتفورمين يمكن أن يكون تدخلاً مفيداً لتعزيز الصحة الأيضية لدى النساء المصابات بمتلازمة المبيض المتعدد الكيسات، على الرغم من تأثيره المحدود على تقليل الوزن. [Extracted from the article]

Background: Women with polycystic ovary syndrome (PCOS) are usually at increased risk of metabolic syndrome and insulin resistance (IR), regardless of their body weight, and the development of type 2 diabetes in those women is not uncommon. Metformin is an oral hypoglycemic drug with a significant role in improving IR and lipid profile in diabetic persons without causing hypoglycemia. Objectives: To study the effectiveness of metformin in reducing body weight, IR, and lipid profile in non-diabetic PCOS women. Materials and Methods: Two hundred women with PCOS were included in the study. Serum was taken from them, and measurement of insulin level, fasting blood sugar (FBS), glycosylated hemoglobin (HbA1c), and lipid profile were performed as a baseline. Metformin tabs of 500 mg twice daily were given for 3 months, and measurement of the previous parameters was also performed following treatment. The results were compared between pre- and post-treatment. Results: The study showed that body mass index was not changed following 3 months of metformin intake, while there was a significant reduction in FBS, serum level of insulin, HbA1c, and Homa-IR following treatment. Together and with the exception of a non-significant mild improvement in serum high-density lipoprotein level, serum levels of cholesterol, triglyceride, and low-density lipoprotein were improved with a significant reduction following metformin treatment. Conclusion: Regardless its ability to reduce body weight, metformin can be effectively used for lowering FBS, lipid profile, and improving IR in non-diabetic PCOS women and can be used as an effective intervention to improve the quality of life in women with PCOS. [ABSTRACT FROM AUTHOR]

Copyright of Medical Journal of Babylon is the property of Wolters Kluwer India Pvt Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)